Table 1.
Analysis | Variable | FTLD | Controls | P-Value |
---|---|---|---|---|
Discovery (n = 2,661) |
n | 62 | 2,599 | NA |
Age at death or last visit (Mean ± SD) | 68.6 ± 7.34 | 85.9 ± 3.55 | < 0.001 | |
Sex (M / F) | 35 / 27 | 1,163 / 1,436 | NS | |
Age of Onset (n = 32)* | 60.0 ± 7.35 | NA | NA | |
Disease Duration (n = 32)* | 9.56 ± 3.58 | NA | NA | |
Pathological Type (Tau / TDP) | 24 / 38 | NA | NA | |
Refined (n = 3,635) |
n | 94 | 3,541 | NA |
Age at death or last visit (Mean ± SD) | 67.8 ± 8.39 | 86.0 ± 3.63 | < 0.001 | |
Sex (M / F) | 49 / 45 | 1,419 / 2,122 | < 0.05 | |
Age of Onset (n = 62)* | 59.2 ± 8.80 | NA | NA | |
Disease Duration (n = 62)* | 8.98 ± 3.32 | NA | NA | |
Pathological Type (Tau / TDP / FUS / UPS) | 51 / 37 / 5 / 1 | NA | NA |
Summary demographic and clinical information for participants included in the discovery and refined analyses. The refined analysis includes 54 FTLD cases and 2,085 controls from the discovery analysis, and an additional 40 FTLD cases and 1,456 controls
Age of onset and disease duration was available for the indicated number of participants included in each analysis. M, male; F, female; SD, standard deviation; NA, not applicable; NS, not significant. TDP, TAR DNA-binding protein 43; FUS, Fused in sarcoma; UPS, ubiquitin positive.